<DOC>
	<DOCNO>NCT02863419</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial investigate efficacy safety oral Semaglutide versus Liraglutide versus Placebo Subjects Type 2 Diabetes Mellitus .</brief_summary>
	<brief_title>Efficacy Safety Oral Semaglutide Versus Liraglutide Versus Placebo Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial Male female , age equal 18 year time signing informed consent . For Japan : Male female , age least 20 year time signing informed consent Diagnosed type 2 diabetes mellitus least 90 day prior day screen . HbA1c ( glycosylated haemoglobin ) 7.09.5 % ( 5380.3 mmol/mol ) ( inclusive ) Stable daily dose metformin ( equal 1500 mg maximum tolerate dose document subject medical record ) alone combination stable daily dose SGLT2 ( sodiumglucose cotransporter2 ) inhibitor least 90 day prior day screen ( fixeddose combination allow ) Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method ( adequate contraceptive measure require local regulation practice ) .For certain specific country : Additional specific requirement apply Any disorder , investigator 's opinion might jeopardise subject 's safety compliance protocol Family personal history Multiple Endocrine Neoplasia Type 2 ( MEN 2 ) Medullary Thyroid Carcinoma ( MTC ) History pancreatitis ( acute chronic ) History major surgical procedure involve stomach potentially affect absorption trial product ( e.g . subtotal total gastrectomy , sleeve gastrectomy , gastric bypass surgery ) Any follow : myocardial infarction ( MI ) , stroke hospitalisation unstable angina transient ischaemic attack within past 180 day prior day screen Subjects presently classify New York Heart Association ( NYHA ) Class IV Planned coronary , carotid peripheral artery revascularisation know day screen Subjects ALT ( alanine aminotransferase ) 2.5 Ã— upper normal limit ( UNL ) Renal impairment define estimate Glomerular Filtration Rate ( eGFR ) 60 mL/min/1.73 m^2 per Chronic Kidney Disease Epidemiology Collaboration formula ( CKDEPI ) Treatment medication indication diabetes obesity state inclusion criterion period 90 day day screen . An exception shortterm insulin treatment acute illness total equal 14 day Proliferative retinopathy maculopathy require acute treatment . Verified fundus photography dilate fundoscopy perform within 90 day prior randomisation History presence malignant neoplasm within last 5 year ( except basal squamous cell skin cancer carcinoma situ ) History diabetic ketoacidosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>